AP Insights, News, Videos, and More

Ananda Scientific has received approval by the FDA for its investigational new drug application for a clinical trial of an investigational drug that uses CBD as an adjunctive treatment for OUD.

The research by the University of California San Francisco is the first to show an association between increased drinking and hospital visits for atrial fibrillation in a large population, as well as the first to link acute alcohol...

Between June 2016 and May 2021, buprenorphine use in correctional settings increased 224-fold in the United States, according to a study published online in JAMA Network Open. Despite the substantial increase, buprenorphine treatment is still...

In a study of 2 rural Massachusetts jails, risk of recidivism after leaving jail was found to be lower among those with opioid use disorder who were offered buprenorphine during their incarceration vs. those who were not.

Social isolation and pandemic-related stress are projected to fuel a continued rise in substance use and poor substance use outcomes across the US, according to a report released last week by the predictive analytics firm Prealize.

In areas where Medicaid coverage is more common, providers of buprenorphine treatment are much less likely to discriminate between prospective patients with Medicaid and those with private insurance, according to a study published in Health...

Opioid overdose-involved deaths among Americans over the age of 55 have increased 10-fold since 1999, and older Black men in particular have been disproportionately impacted, according to a study published this week by JAMA Network Open.

Submissions for abstracts are now being accepted for the Cocaine, Meth & Stimulant Summit, which will be held November 2-4, 2022. The deadline to submit an abstract for consideration is March 1.

Warriors Heart, the Texas-based program that treats active duty military, veterans, first responders, and EMTs/paramedics, has announced the launch of a new extended recovery program to facilitate patient transitions to life after treatment.

Opioid prescriptions dispensed by retail pharmacies declined by 21% from 2008 to 2018, but variances were observed based on geographic area, types of patients, and types of prescribers, according to research recently released by RAND Corp.